Key Takeaways
- Hubble Therapeutics has secured $7.3 million in Series A funding to further develop a gene therapy for pediatric blindness.
- The company’s lead candidate, HUB-101, targets severe retinal diseases LCA16 and SVD, with plans to enter clinical trials in 2026.
- HBU-101 has received FDA designations as a Rare Pediatric Disease and Orphan Drug, underscoring its promise in treating rare conditions.
Funding for Innovative Gene Therapy
Hubble Therapeutics, a biotechnology firm based in Hanover, NH, focused on developing solutions for pediatric blindness, has announced the successful closing of a $7.3 million Series A funding round. The investment will be pivotal in advancing the company’s flagship product, HUB-101, into human clinical trials.
Hubble Therapeutics is dedicated to addressing Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two progressive retinal diseases that result in severe vision impairment in children and adults alike. This research is based on the work of Professor Bikash Pattnaik at the University of Wisconsin-Madison and is licensed through the Wisconsin Alumni Research Foundation (WARF).
HUB-101 has garnered FDA designations that include Rare Pediatric Disease Designation and Orphan Disease Designation, acknowledging its potential in treating these rare degenerative conditions. In addition to internal development efforts, Hubble Therapeutics has formed strategic partnerships with Andelyn Biosciences in Columbus, Ohio, and Virscio in New Haven, Connecticut. These collaborations are aimed at the development, manufacturing, and completion of IND-enabling studies, which are critical milestones in the regulatory process.
Looking ahead, Hubble Therapeutics plans to initiate Phase I/II clinical trials for HUB-101 in 2026. These trials are designed to assess the safety and effectiveness of the treatment, with the ultimate goal of providing a potential cure for the patients affected by LCA16 and SVD.
Overall, Hubble Therapeutics is making significant strides in its mission to develop cutting-edge gene therapies, which could transform the treatment landscape for pediatric blindness and offer new hope to families affected by these debilitating conditions.
The content above is a summary. For more details, see the source article.